Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.
The post Study: Roxadustat Effectively Treats…
[mc4wp_form id="449"]
An analysis of contemporary ESA utilization among patients with anemia of nondialysis-dependent chronic kidney disease may help identify optimal candidates for treatment….
Comorbidities and advanced CKD were prevalent among the approximately 275,000 patients with anemia of CKD from the international DISCOVER CKD cohort.
The…
Early detection of iron status may improve cardiovascular risk assessment in patients with CKD, according to investigators.
The post Heart Failure Hospitalizations Linked…
Investigators sought to define an ESA dosing regimen that reduces the likelihood of transfusion while minimizing any potential cardiovascular risks.
The post RBC…
Percentage of donations with antibodies has risen steadily over time, according to the Red Cross
The post COVID-19 Antibodies Found in 1 in…
Certain groups of patients with nondialysis-dependent chronic kidney disease (CKD) require additional management to control their hemoglobin levels (Hb), according to investigators. In the national Swedish Renal Registry,…
In addition to its ability to reduce glucose and blood pressure, canagliflozin might reduce the risk for the development of anemia and initiation of anemia treatments in patients…
Perioperative blood transfusion may not increase the risk for acute rejection, graft loss, or death in non-sensitized kidney transplant recipients receiving maintenance immunosuppressive therapy. In a study of…
The Food and Drug Administration has set a new Prescription Drug User Fee Act (PDUFA) date for the New Drug Application for roxadustat. The Agency announced that additional…